Table 1. Patient characteristics.
Values at P < 0.05 were considered statistically significant.
WBC, white blood cell; Hb, hemoglobin; Plt, platelet; LD, lactate dehydrogenase; BM, bone marrow; CNS, central nervous system; TKI, tyrosine kinase inhibitor; CMR, complete molecular remission; HSCT, allogeneic hematopoietic stem cell transplantation; PBSC, peripheral blood stem cell
| Total (n=23) | IM/DAS (n=10) | PON (n=13) | P-value | |
| Gender, n (%) | 1 | |||
| Male | 10 (43) | 4 (40) | 6 (46) | |
| Female | 13 (57) | 6 (60) | 7 (54) | |
| Age at diagnosis, median (range) | 53 (28-67) | 46 (31-60) | 57 (28-67) | 0.13 |
| 20-64, n (%) | 21 (91) | 10 (100) | 11 (85) | |
| ≧65, n (%) | 2 (9) | 0 (0) | 2 (15) | |
| Labo data at diagnosis, median (range) | ||||
| WBC (×103/μL) | 22.6 (2.2-679.2) | 22.5 (1.6-524.8) | 22.6 (3.6-679.2) | 0.47 |
| Hb (g/dL) | 11.5 (4.3-14.7) | 8.3 (4.3-18.5) | 12.7 (5.5-14.7) | 0.079 |
| Plt (×103/μL) | 63 (3-306) | 54 (3-171) | 70 (3-306) | 0.66 |
| LD (IU/L) | 847 (242-7,162) | 715 (291-1,938) | 992 (242-7,162) | 0.41 |
| BM blast (%) | 89.8 (21.6-97.2) | 94.9 (60-97.2) | 83.8 (21.6-96.4) | 0.007 |
| BCR::ABL1 mRNA (copy/μgRNA) | 2.2×105 (1.9×102-9.5×105) | 2.0×104 (1.9×102-9.5×105) | 2.2×105 (4.4×104-9.5×105) | 0.22 |
| CD20 >20%, n (%) | 6 (26) | 4 (40) | 2 (15) | 0.34 |
| ECOG performance status, n (%) | 1 | |||
| 0-1 | 22 (96) | 10 (100) | 12 (92) | |
| ≧2 | 1 (4) | 0 (0) | 1 (8) | |
| Cytogenetic abnormalities, n (%) | 0.65 | |||
| t(9;22) isolated | 6 (26) | 2 (20) | 4 (31) | |
| t(9;22) with additional chromosomal abnormalities | 16 (70) | 8 (80) | 8 (62) | |
| Unknown | 1 (4) | 0 (0) | 1 (8) | |
| Isoform, n (%) | 1 | |||
| p190(minor) | 11 (49) | 5 (50) | 6 (46) | |
| p210(major) | 11 (49) | 4 (40) | 7 (54) | |
| Unknown | 1 (4) | 1 (10) | 0 (0) | |
| CNS involvement, n (%) | 3 (13) | 2 (20) | 1 (8) | 0.56 |
| TKI, n (%) | ||||
| Imatinib | 6 (26) | 6 (60) | 0 (0) | |
| Dasatinib | 4 (17) | 4 (40) | 0 (0) | |
| Ponatinib | 13 (57) | 0 (0) | 13 (100) | |
| CMR within 3 month, n (%) | 18 (78) | 6 (60) | 12 (92) | 0.13 |
| HSCT, n (%) | 16 (70) | 9 (90) | 7 (54) | 0.089 |
| PBSC of matched related donor | 4 (25) | 4 (44) | 0 (0) | |
| BM of matched unrelated donor | 4 (25) | 3 (33) | 1 (14) | |
| BM of mismatched unrelated donor | 5 (31) | 1 (11) | 4 (57) | |
| Cord blood | 3 (19) | 1 (11) | 2 (29) | |
| Maintenance therapy | ||||
| Post HSCT, n (%) | 0 (0) | 0 (0) | 0 (0) | 1 |
| Without HSCT, n (%) | 6 (85) | 0 (0) | 6 (100) | 0.008 |
| ABL mutation, n (%) | 1 (4) | 1 (10) | 0 (0) | 0.44 |